Skip to main content
TipRanks
Go Ultimate75% OFF

Altimmune (3G0) Stock Statistics & Valuation Metrics

9 Followers

Total Valuation

Altimmune has a market cap or net worth of EUR 290.41M. The enterprise value is EUR 358.18M.

Market Cap
EUR 290.41M
Enterprise Value
EUR 358.18M

Share Statistics

Altimmune has 194,589,450 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
194,589,450
Owned by Insiders
0.48%
Owned by Institutions
39.74%

Financial Efficiency

Altimmune’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -35.36%.

Return on Equity (ROE)
-0.39
Return on Assets (ROA)
-0.31
Return on Invested Capital (ROIC)
-35.36%
Return on Capital Employed (ROCE)
-0.36
Revenue Per Employee
719.298
Profits Per Employee
-1.55M
Employee Count
57
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Altimmune is -2.28. Altimmune’s PEG ratio is -0.05.

PE Ratio
-2.28
PS Ratio
12311.52
PB Ratio
0.76
Price to FCF
-3.12
Price to Operating Cash Flow
-3.30
PEG Ratio
-0.05

Income Statement

In the last 12 months, Altimmune had revenue of 41.00K and earned -88.09M in profits. Earnings per share was -1.00.

Revenue
41.00K
Gross Profit
41.00K
Operating Income
-94.49M
Pretax Income
-88.77M
Net Income
-88.09M
EBITDA
-87.03M
Earnings Per Share (EPS)
-1.00

Cash Flow

In the last 12 months, operating cash flow was -102.36M and capital expenditures -118,000, giving a free cash flow of -102.47M billion.

Operating Cash Flow
-102.36M
Free Cash Flow
-102.47M
Free Cash Flow per Share
-0.50

Dividends & Yields

Altimmune pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-32.01%
Earnings Yield
-30.90%

Stock Price Statistics

Beta
0.60
52-Week Price Change
-56.60%
50-Day Moving Average
2.28
200-Day Moving Average
2.63
Relative Strength Index (RSI)
30.93
Average Volume (3m)
3,938

Important Dates

Altimmune upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 03, 2027
Ex-Dividend Date
―

Financial Position

Altimmune as a current ratio of 18.55, with Debt / Equity ratio of 15.87%

Current Ratio
18.55
Quick Ratio
18.55
Debt to Market Cap
0.11
Net Debt to EBITDA
0.09
Interest Coverage Ratio
-57.76

Taxes

In the past 12 months, Altimmune has paid -681.00K in taxes.

Income Tax
-681.00K
Effective Tax Rate
0.01

Enterprise Valuation

Altimmune EV to EBITDA ratio is -3.27, with an EV/FCF ratio of -3.20.

EV to Sales
12592.83
EV to EBITDA
-3.27
EV to Free Cash Flow
-3.20
EV to Operating Cash Flow
-3.20

Balance Sheet

Altimmune has EUR 265.06M in cash and marketable securities with EUR 36.20M in debt, giving a net cash position of EUR 228.86M billion.

Cash & Marketable Securities
EUR 265.06M
Total Debt
EUR 36.20M
Net Cash
EUR 228.86M
Net Cash Per Share
EUR 1.18
Tangible Book Value Per Share
EUR 2.16

Margins

Gross margin is -238196.15%, with operating margin of -442580.77%, and net profit margin of -401361.54%.

Gross Margin
-238196.15%
Operating Margin
-442580.77%
Pretax Margin
-401361.54%
Net Profit Margin
-401361.54%
EBITDA Margin
-385076.92%
EBIT Margin
-385353.85%

Analyst Forecast

The average price target for Altimmune is EUR 14.52, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 14.52
Price Target Upside
837.73% Upside
Analyst Consensus
Strong Buy
Analyst Count
3
Revenue Growth Forecast
23.22%
EPS Growth Forecast
35.42%

Scores

Smart Score
6
AI Score
―